The Trump Administration should not put the public at risk by empowering an
anti-vaccine crackpot
View this email in your browser →
<[link removed]>
<[link removed]>
"Vaccinations are one of the biggest public-health accomplishments of the 20th
century, having saved millions of lives in the US and around the world… Loss of
public support for them -- and for future vaccine developments would have
devastating consequences."
<[link removed]>
-- Mike Bloomberg
"RFK Jr. Is Too Dangerous for Government"
November 2024
<[link removed]>
READ MORE
<[link removed]>
<[link removed]>
<[link removed]>
<[link removed]>
John,
In an op-ed published today, Mike warns about the danger of Donald Trump
appointing "anti-vaccine crusader and peddler of junk science" Robert F.
Kennedy Jr. to his administration.
"It would be a disastrous mistake," Mike writes, "that would kill and sicken
countless Americans while also harming Trump's political standing and
tarnishing his first-term legacy."
READ MIKE'S OP-ED
<[link removed]>
<[link removed]>
<[link removed]>
<[link removed]>
Bringing Kennedy into the second Trump administration and giving him
influence -- or authority -- over public health policy would amplify science
denial and could cause extensive harm, especially to children. "Want to see a
return of measles, mumps, and rubella in the schools across the country?
Appoint Kennedy. Want to see more people die from Covid? Appoint Kennedy. Want
to see spikes in diphtheria? Appoint Kennedy," Mike writes.
Donald Trump ended his first term by initiating the rapid development of a
life-saving Covid-19 vaccine. To protect the public health of all Americans --
and safeguard his own legacy -- he should not undermine the life-saving power
of all vaccines in his second term.
Read Mike's full op-ed here:
[link removed]
<[link removed]>
Thanks,
MikeBloomberg.com
<[link removed]> <[link removed]>
<[link removed]>
<[link removed]>
<[link removed]>
Click here to unsubscribe
<[link removed]>
.
Click here to read our privacy policy. <[link removed]>
Mike Bloomberg
All content ©2024 Bloomberg IP Holdings LLC. All rights reserved.